References
- World Health Organisation. The top 10 causes of death [Internet]. Geneva: World Health Organization; 2018 [cited 116, 2018]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
- Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Prognostic relevance of pathological sympathetic activation after acute thromboembolic stroke. Neurology. 2001;57:833–838. doi:10.1212/WNL.57.5.83311552013
- Xiong L, Tian G, Leung H, et al. Autonomic dysfunction predicts clinical outcomes after acute ischemic stroke: a prospective observational study. Stroke. 2018;49:215–218. doi:10.1161/STROKEAHA.117.01931229203690
- Barron SA, Rogovski Z, Hemli J. Autonomic consequences of cerebral hemisphere infarction. Stroke. 1994;25:113–116. doi:10.1161/01.STR.25.1.1138266357
- Sykora M, Diedler J, Poli S, et al. Autonomic shift and increased susceptibility to infections after acute intracerebral hemorrhage. Stroke. 2011;42:1218–1223. doi:10.1161/STROKEAHA.110.60463721393593
- Chamorro A, Amaro S, Vargas M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci. 2007;252:29–35. doi:10.1016/j.jns.2006.10.00117129587
- Prass K, Meisel C, Höflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell Type 1-like immunostimulation. J Exp Med. 2003;198:725–736. doi:10.1084/jem.2002109812939340
- Savitz SI, Erhardt JA, Anthony JV, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab. 2000;20:1197–1204. doi:10.1097/00004647-200008000-0000510950380
- Lysko PG, Lysko KA, Yue TL, Webb CL, Gu JL, Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke. 1992;23:1630–5; discussion 1635–1636.
- Heeba GH, El-Hanafy AA. Nebivolol regulates eNOS and iNOS expressions and alleviates oxidative stress in cerebral ischemia/reperfusion injury in rats. Life Sci. 2012;90:388–395. doi:10.1016/j.lfs.2011.12.00122226906
- Standefer M, Little JR. Improved neurological outcome in experimental focal cerebral ischemia treated with propranolol. Neurosurgery. 1986;18:136–140. doi:10.1227/00006123-198602000-000033960288
- Laowattana S, Oppenheimer SM. Protective effects of beta-blockers in cerebrovascular disease. Neurology. 2007;68:509–514. doi:10.1212/01.wnl.0000253186.23949.fd17296916
- Kinnander G, Viitanen M, Asplund K. Beta-adrenergic blockade after stroke. A preliminary closed cohort study. Stroke. 1987;18:240–243. doi:10.1161/01.STR.18.1.2402880414
- Dowlatshahi D, Fang J, Kawaja M, Hakim A. Use of calcium channel blockers after stroke is not associated with poor outcome: a cohort from the registry of the Canadian stroke network. J Neurol. 2006;253:1478–1483. doi:10.1007/s00415-006-0249-116786208
- Yu AYX, Keezer MR, Zhu B, Wolfson C, Côté R. Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc Dis. 2009;27:398–402. doi:10.1159/00020744419276623
- Heeley EL, Wei JW, Wang J-G, et al. Comparative effects of antihypertensive drugs on stroke outcome in China. Int J Stroke. 2014;9(Suppl A100):113–118. doi:10.1111/ijs.1233025042450
- Tziomalos K, Giampatzis V, Bouziana SD, et al. Effect of antihypertensive treatment on the long-term outcome of patients discharged after acute ischemic stroke. Clin Exp Hypertens. 2017;39:246–250. doi:10.1080/10641963.2016.124656128448189
- Aerden L, van Raak E, Boreas A, Kessels A, Lodder J. Common drugs in acute ischemic stroke and their influence on outcome: an observational study in 1013 stroke patients. Clin Neuropharmacol. 2008;31:74–79. doi:10.1097/WNF.0b013e31811ec14218382178
- Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. doi:10.1371/journal.pmed.100010019621070
- Sulter G, Steen C, De Keyser J. Use of the barthel index and modified rankin scale in acute stroke trials. Stroke. 1999;30(8):1538–1541. doi:10.1161/01.STR.30.8.153810436097
- Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1691. doi:10.1001/jama.280.19.16909832001
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi:10.1136/bmj.327.7414.55712958120
- Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet]. The Cochrane Collaboration; 2011 [updated 3, 2011; cited 123, 2018]. Available from: http://handbook-5-1.cochrane.org/.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. doi:10.1016/0197-2456(86)90046-23802833
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi:10.1136/bmj.315.7109.6299310563
- Swedish Agency For Health Technology Assessment And Assessment Of Social Services. Assessment of methods in health care A handbook [Internet]. 2018 [cited 122, 2018]. Available from: https://www.sbu.se/contentassets/76adf07e270c48efaf67e3b560b7c59c/eng_metodboken.pdf.
- Koton S, Tanne D, Grossman E. Prestroke treatment with beta-blockers for hypertension is not associated with severity and poor outcome in patients with ischemic stroke: data from a national stroke registry. J Hypertens. 2017;35:870–876. doi:10.1097/HJH.000000000000121828030430
- Eizenberg Y, Grossman E, Tanne D, Koton S. Pre admission treatment with Beta-blockers in hypertensive patients with acute stroke and 3-month outcome—Data from a national stroke registry. J Clin Hypertens. 2018;20:568–572. doi:10.1111/jch.13211
- Sundbøll J, Schmidt M, Horváth-Puhó E, et al. Impact of preadmission treatment with calcium channel blockers or beta blockers on short-term mortality after stroke: a nationwide cohort study. BMC Neurol. 2015;15:24. doi:10.1186/s12883-015-0279-325884780
- Dziedzic T, Slowik A, Pera J, Szczudlik A. Beta-blockers reduce the risk of early death in ischemic stroke. J Neurol Sci. 2007;252:53–56. doi:10.1016/j.jns.2006.10.00717134722
- Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (‘BEST’ trial): an evaluation. Br Med J. 1988;296:737–741. doi:10.1136/bmj.296.6624.7373126956
- Dowlatshahi D, Hakim A, Fang J, Sharma M. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network. Int J Stroke. 2009;4:328–334. doi:10.1111/j.1747-4949.2009.00331.x19765119
- Potter J, Mistri A, Brodie F, et al. Controlling hypertension and hypotension immediately post stroke (CHHIPS)–a randomised controlled trial. Health Technol Assess. 2009;13:1–73. doi:10.3310/hta13090
- Kalita J, Misra UK, Kumar B. Is β-blocker (atenolol) a preferred antihypertensive in acute intracerebral hemorrhage? Neurol Sci. 2013;34:1099–1104. doi:10.1007/s10072-012-1210-y23053838
- Shoup JP, Winkler J, Czap A, et al. β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage. J Neurol Sci. 2014;336:127–131. doi:10.1016/j.jns.2013.10.02224183854
- Maier IL, Karch A, Mikolajczyk R, Bähr M, Liman J. Effect of beta-blocker therapy on the risk of infections and death after acute stroke–a historical cohort study. PLoS One. 2015;10:e0116836. doi:10.1371/journal.pone.011683625643360
- Phelan C, Alaigh V, Fortunato G, Staff I, Sansing L. Effect of β-adrenergic antagonists on in-hospital mortality after ischemic stroke. J Stroke Cerebrovasc Dis. 2015;24:1998–2004. doi:10.1016/j.jstrokecerebrovasdis.2015.04.03526163891
- Sykora M, Siarnik P, Diedler J; VISTA Acute Collaborators. β-blockers, pneumonia, and outcome after ischemic stroke: evidence from virtual international stroke trials archive. Stroke. 2015;46:1269–1274. doi:10.1161/STROKEAHA.114.00826025899243
- Tziomalos K, Giampatzis V, Bouziana SD, et al. Effects of different classes of antihypertensive agents on the outcome of acute ischemic stroke. J Clin Hypertens. 2015;17:275–280. doi:10.1111/jch.12498
- Westendorp WF, Vermeij J-D, Brouwer MC, et al. Pre-stroke use of beta-blockers does not lower post-stroke infection rate: an exploratory analysis of the preventive antibiotics in stroke study. Cerebrovasc Dis. 2016;42:506–511. doi:10.1159/00045092627701170
- Starr JB, Tirschwell DL, Becker KJ. Labetalol use is associated with increased in-hospital infection compared with nicardipine use in intracerebral hemorrhage. Stroke. 2017;48:2693–2698. doi:10.1161/STROKEAHA.117.01723028904237
- Starr JB, Tirschwell DL, Becker KJ. Increased infections with β-blocker use in ischemic stroke, a β2-receptor mediated process? Neurol Sci. 2017;38:967–974. doi:10.1007/s10072-017-2877-x28258316
- Maier IL, Becker JC, Leyhe JR, et al. Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. PLoS One. 2018;13:e0196174. doi:10.1371/journal.pone.019617429694433
- Sykora M, Putaala J, Meretoja A, Tatlisumak T, Strbian D. Beta-blocker therapy is not associated with mortality after intracerebral hemorrhage. Acta Neurol Scand. 2018;137:105–108. doi:10.1111/ane.1281728869294
- Fuentes B, Fernández-Domínguez J, Ortega-Casarrubios MA, SanJosé B, Martínez-Sánchez P, Díez-Tejedor E. Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens. 2010;28:575–581. doi:10.1097/HJH.0b013e3283350f5020090554
- De Raedt S, Haentjens P, De Smedt A, et al. Pre-stroke use of beta-blockers does not affect ischaemic stroke severity and outcome. Eur J Neurol. 2012;19:234–240. doi:10.1111/j.1468-1331.2011.03475.x21777353
- Barer DH. The influence of visual and tactile inattention on predictions for recovery from acute stroke. QJM. 1990;74:21–32.2326433
- Klehmet J, Hoffmann S, Walter G, Meisel C, Meisel A. Stroke induces specific alteration of T memory compartment controlling auto-reactive CNS antigen-specific T cell responses. J Neurol Sci. 2016;368:77–83. doi:10.1016/j.jns.2016.06.03927538605